EUCTR2005-001388-71-CZ进行中（未招募）不适用
A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis.Revised Protocol 02, Incorporates Amendments 02, 04 and Administrative Letter dated 14-Apr-2006;+ Pharmacogenetics Blood Sample Amendment version 01 dated 29-June-2005. - Botticelli
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Confirmed acute symptomatic DVT, i.e., proximal or extensive calf-vein thrombosis, involving at least the upper third part of the deep calf veins (trifurcation area) without concomitant symptomatic PE
- •2) Written informed consent.
- •3) Women and men, ages 18 (or legal age of consent) to 90.
- •Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 1 week after the study in such a manner that the risk of pregnancy is minimized.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Legal lower age limitations (country specific)
- •2) Women who are pregnant or breastfeeding.
- •3) Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT
- •4) Indications for VKA other than DVT
- •5) More than 24 hours pre-randomization treatment with therapeutic dosages of UFH, LMWH or fondaparinux or more than a single starting dose of VKA prior to randomization
- •6) Receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of apixaban (with the exception of approved medications being used for an approved indication, e.g., investigating a
- •new dosing regimen for an approved indication).
- •7) Creatinine clearance < 30 ml/min, impaired liver function (ALT > 3 x ULN), or bacterial endocarditis
- •8) Life expectancy <6 months
- •9) Active bleeding or high risk for bleeding contraindicating treatment with LMWH, fondaparinux or VKA
- •10) Systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg
- •11) Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness
- •12) Any other contraindication listed in the local labeling of warfarin, acenocoumarol, phenprocoumon, fondaparinux, enoxaparin, or tinzaparin
- •13) Use of acetylsalicylic acid (ASA) > 165 mg/day.
- •14) WOCBP who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to 1 week after the study.
- •15) Women with a positive pregnancy test on enrollment or prior to study drug administration.
- •16) Concomitant administration of: Azole antifungals (e.g., ketoconazole), HIV protease inhibitors (e.g., ritonavir) and macrolide antibiotics (e.g., erythromycin).
- •Note: topical azole antifungal agents are permitted.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis.Revised Protocol 02, Incorporates Amendments 02, 04 and Administrative Letter dated 14-Apr-2006;+ Pharmacogenetics Blood Sample Amendment version 01 dated 29-June-2005. - BotticelliEUCTR2005-001388-71-SEBristol-Myers Squibb International Corporation660
进行中（未招募）
不适用
A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis.Protocol version 3.0 dated 29-June-2005 - BotticelliEUCTR2005-001388-71-ATBristol-Myers Squibb International Corporation660
进行中（未招募）
不适用
A phase 2 randomized, parallel-arm study of oral direct factor Xa-inhibitor apixaban and low molecular weight heparin or fondaparinux with a vitamin K antagonist in subjects with acute symptomatic deep vein thrombosis.Treatment of subjects with acute syntomatic deep vein thrombosis.MedDRA version: 9.1Level: HLTClassification code 10034572Term: Peripheral embolism and thrombosisEUCTR2005-001388-71-ITBRISTOL-M.SQUIBB660
进行中（未招募）
不适用
A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta®) as Second Line Therapy in Patients with Advanced or Metastatic Non Small Cell Lung Cancer - N/AAdvanced or Metastatic Non Small Cell Lung CancerMedDRA version: 9.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2006-006698-25-DEEli Lilly and Company Limited160
进行中（未招募）
1 期
A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta®) as Second Line Therapy in Patients with Advanced or Metastatic Non Small Cell Lung Cancer - N/AAdvanced or Metastatic Non Small Cell Lung CancerMedDRA version: 9.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2006-006698-25-FREli Lilly and Company limited160